Lisocabtagene maraleucel may induce remission in relapsed chronic lymphocytic leukemia (CLL)
Bookmark1. Complete response or remission was reported in 18% of patients who received a single...
Read MoreAug 31, 2023
Bookmark1. Complete response or remission was reported in 18% of patients who received a single...
Read MoreAug 30, 2023
Bookmark1. In this systematic review and network meta-analysis, aerobic exercise training, dynamic...
Read MoreAug 30, 2023
Bookmark1. Body weight reduction at week 72 was significantly greater with tirzepatide versus...
Read MoreAug 28, 2023
Bookmark1. For women with infertility on assisted reproductive technologies (ART), higher...
Read MoreAug 26, 2023
Bookmark1. In this randomized controlled trial, a high dose of GNT0003 gene therapy was associated...
Read MoreAug 25, 2023
Bookmark1. Mean MADRS change at week 6 was -8.2 in the active tDCS group versus -8.0 in the sham...
Read MoreAug 25, 2023
Bookmark1. In this randomized controlled trial, there were no significant differences in the...
Read MoreAug 25, 2023
Bookmark1. The risk of mortality from solid cancer, lagged by 10 years, is estimated to be...
Read MoreAug 24, 2023
Bookmark1. Patients with inappropriate hospital admission (IHA) experience twice more adverse...
Read MoreAug 23, 2023
Bookmark1. HbA1c and bodyweight reduction were greater in the retatrutide group compared to...
Read MoreAug 22, 2023
Bookmark1. In this cross-sectional study, there was a negative association between sleep duration...
Read MoreAug 22, 2023
Bookmark1. 5-year recurrence incidence was 2.5% at follow-up. 2. Overall survival at 5 years...
Read MoreAug 22, 2023
Bookmark1. Median progression-free survival was shown to be 27.7 months in the vorasidenib group...
Read MoreAug 19, 2023
Bookmark1. This phase 2, single-arm, multicenter trial found that in HER2-positive breast cancer...
Read MoreAug 17, 2023
Bookmark1. Patients assigned to orforglipron experienced significant reductions in HbA1c, and body...
Read MoreAug 16, 2023
Bookmark1. Median overall survival in the atezolizumab group was 10.3 months versus 9.2 months in...
Read MoreAug 15, 2023
Bookmark1. The pathological complete response rate for the experimental group was improved...
Read MoreAug 15, 2023
Bookmark1. At 24 months, more participants in the pembrolizumab group were alive without an event,...
Read MoreAug 15, 2023
Bookmark1. There was no statistically significant difference in recovery time in patients with...
Read MoreAug 14, 2023
Bookmark1. Anxiety and depression were more prevalent among individuals with eczema or psoriasis,...
Read More